Results for this period
Full year1 June 2025 to 31 May 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Dispensing pharmacy sales increased as the number of stores grew through M&A. Profit increased owing to improved profitability in the dispensing pharmacy business, contributions from existing and acquired stores, and lower selling, general and administrative expenses resulting from more efficient head-office operations. The retail business recorded lower revenue and profit due to the closure of unprofitable stores, new competitor openings, and weak sales of seasonal medicines. The medical mall management business was affected by the departure of medical institutions from some tenant locations, while the Other business was affected by a decline in the number of contracts concluded and visits, as well as depreciation and amortization expenses arising from new product development.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 June 2025 to 31 May 2026 |
| Net Sales | ¥69,512 million (YoY +9.5%) |
| Operating profit | ¥979 million (YoY +233.5%) |
| Ordinary income | ¥715 million (YoY +422.4%) |
| Profit attributable to owners of the parent | ¥114 million |
| Net income per share | ¥10.01 |
| Operating Margin | 1.4% |
| Equity ratio | End of the current fiscal period 20.3% / End of previous period 20.9% |
| Total assets | ¥32,680 million |
| Net assets | ¥6,859 million |
| Cash flows from operating activities | ¥3,278 million |
| Cash flows from investing activities | ¥-1,975 million |
| Cash flows from financing activities | ¥-181 million |
| Cash and cash equivalents at end of period | ¥6,012 million |
| Full-year earnings forecast | Net Sales ¥70,604 million (YoY +1.6%) / Operating profit ¥1,014 million (YoY +3.5%) / Ordinary income ¥736 million (YoY +2.9%) / Profit attributable to owners of the parent ¥11 million (YoY -90.0%) |
| Annual Dividend Forecast | ¥14 → ¥14（0.0%） |
| Payout ratio | 139.8% |
| Segment revenue | Dispensing Pharmacy Business ¥59,331 million (YoY +12.7%), Retail Business ¥8,042 million (YoY -7.5%), Medical Records Storage and Management Business ¥647 million (YoY +6.1%), Medical mall management business ¥505 million (YoY -1.3%) |
| Segment profit | Dispensing Pharmacy Business ¥1,386 million (YoY +139.8%), Retail Business ¥-83 million, Medical Records Storage and Management Business ¥100 million (YoY +95.1%), Medical mall management business ¥87 million (YoY -15.2%) |
| Depreciation and amortization | ¥782 million |
| Impairment loss | ¥48 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥19 million, Reversal of allowance for doubtful accounts ¥27 million, Subsidy Income ¥61 million / Extraordinary loss Loss on sale of fixed assets ¥1 million, Loss on Disposal of Fixed Assets ¥7 million, Loss on reduction of fixed assets ¥60 million, Impairment Losses ¥48 million, Loss on cancellation of lease agreements ¥7 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 3 / Company name 株式会社三幸メディカル, 大洋薬品株式会社, 有限会社平成薬品 / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 12,060,381 Shares |
| Treasury Shares at Period-End | 557,856 Shares |
| Factors Behind Changes in Business Performance | Dispensing pharmacy sales increased as the number of stores grew through M&A. Profit increased owing to improved profitability in the dispensing pharmacy business, contributions from existing and acquired stores, and lower selling, general and administrative expenses resulting from more efficient head-office operations. The retail business recorded lower revenue and profit due to the closure of unprofitable stores, new competitor openings, and weak sales of seasonal medicines. The medical mall management business was affected by the departure of medical institutions from some tenant locations, while the Other business was affected by a decline in the number of contracts concluded and visits, as well as depreciation and amortization expenses arising from new product development. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The increase in the number of stores through M&A led to higher dispensing pharmacy sales. Other factors contributing to the increase in profit were improved profitability in the dispensing pharmacy business, contributions from existing and acquired stores, and lower selling, general and administrative expenses resulting from more efficient head-office operations.